ACTRIS renews MOU with Thermo Fisher Scientific
Topics
Partnerships
13 November 2025
ACTRIS and Thermo Fisher Scientific have renewed their MOU to advance cell and gene therapy in Singapore. Together, they will develop local talent and boost manufacturing capabilities in the region.

🤝  Advancing Cell & Gene Therapy Through Continued Partnership
We are pleased to announce the renewal of our Memorandum of Understanding (MOU) with Thermo Fisher Scientific (opens in new tab), reaffirming our shared commitment to advancing cell and gene therapy manufacturing and innovation in Singapore.
This renewed partnership builds on our ongoing collaboration to establish a joint laboratory that supports cell and gene therapy processes, leveraging on Thermo Fisher Scientific’s expertise and advanced technologies as well as ACTRIS’ infrastructure and projects to accelerate translational and clinical outcomes.
Together, we aim to continue developing skilled local talent, enhancing process development capabilities, and fostering a robust cell and gene therapy ecosystem in the region.
We look forward to another successful phase of partnership with Thermo Fisher Scientific — driving innovation, collaboration, and growth within Singapore’s cell and gene therapy landscape. 🌱
